▁with dra wn ▁from ▁the ▁market ▁( ro f ec ox ib , ▁in ▁September ▁ 2 0 0 4 ▁and ▁val de co x ib ▁in ▁April ▁ 2 0 0 5 ). ▁In ▁addition , ▁the ▁United ▁States ▁Food ▁and ▁D rug ▁Administration ▁and ▁the ▁European ▁Medic ines ▁Agency ▁started ▁revision ▁processes ▁of ▁the ▁entire ▁class ▁of ▁both ▁NS A ID s ▁and ▁CO X - 2 ▁in hib itors . ▁ ▁In ▁April ▁ 2 0 0 7 , ▁the ▁F DA ▁issued ▁Mer ck ▁a ▁non - appro v able ▁letter ▁for ▁et or ico x ib . ▁The ▁letter ▁said ▁Mer ck ▁needs ▁to ▁provide ▁more ▁test ▁results ▁showing ▁that ▁the ▁drug ' s ▁benefits ▁out we igh ▁its ▁ris ks ▁before ▁it ▁has ▁another ▁chance ▁of ▁getting ▁approved . ▁ ▁Brand ▁names ▁Brand ▁names ▁for ▁et or ico x ib ▁include : ▁Alg ix ▁and ▁T aux ib ▁in ▁Italy ▁Ar co x , ▁Ber rica , ▁and ▁Star co x ▁in ▁Pakistan ▁Ar co x ia ▁in ▁Spain , ▁Portugal , ▁Egypt , ▁Sa udi ▁Arab ia , ▁Sweden , ▁Finland , ▁Norway , ▁Est onia , ▁Germany , ▁Greece , ▁Lith u ania , ▁Luxemb ourg , ▁Chile , ▁China , ▁Hong ▁Kong , ▁Hung ary , ▁Indones ia , ▁Ireland , ▁Israel , ▁Jordan , ▁Leb anon , ▁Brazil , ▁Malays ia , ▁Singapore , ▁Th ailand , ▁Gu atem ala , ▁Mexico , ▁Bulg aria , ▁Costa ▁Rica , ▁Philippines , ▁E cuador